emlenoflast   Click here for help

GtoPdb Ligand ID: 12172

Synonyms: Inzomelid | MCC-7840 | MCC7840
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Emlenoflast (MCC7840 [2]; formerly IZD 174) is one of a growing number of NLRP3 inflammasome inhibitors that have been developed for anti-inflammatory potential [3]. It was developed by Inflazome (acquired by Roche in 2020) as an orally bioavailable drug that is able to cross the blood-brain barrier.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 101.47
Molecular weight 388.16
XLogP 3.6
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NS(=O)(=O)c1ccn(n1)C(C)C)Nc1c2CCCc2cc2c1CCC2
Isomeric SMILES CC(C)n1ccc(n1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2c1CCC2
InChI InChI=1S/C19H24N4O3S/c1-12(2)23-10-9-17(21-23)27(25,26)22-19(24)20-18-15-7-3-5-13(15)11-14-6-4-8-16(14)18/h9-12H,3-8H2,1-2H3,(H2,20,22,24)
InChI Key MTOUOUSKXWSTAX-UHFFFAOYSA-N
Immunopharmacology Comments
Emlenoflast inhibits the activity of inflammasomes that contain NLRP3. It is proposed as a treatment for autoinflammatory disorders, including neuroinflammation caused by an NLRP3-mediated inflammatory response by microglia that might be associated with psychiatric brain disorders, stroke or brain trauma.